Manufacturer

Name NDC

Name of Prescription Drug

AvKare, Inc. 42291-0439-30 Emitricitabine and Tenofovir Disoproxil Fumarate 200mg/300mg

| Strength    | Pack Size/Volume | WAC (as of date of commercial availability) | Date of<br>Commercial<br>Availability | Estimated volume of patients who may be prescribed drug |
|-------------|------------------|---------------------------------------------|---------------------------------------|---------------------------------------------------------|
| 200mg/300mg | 30               | \$861.36                                    | 4/12/2021                             | N/A                                                     |

| Breakthrough          |                  |                                                     |                                                                                      |
|-----------------------|------------------|-----------------------------------------------------|--------------------------------------------------------------------------------------|
| therapy               | Priority         | Date and price of acquisition if the                |                                                                                      |
| designation?<br>(Y/N) | Review?<br>(Y/N) | drug was not developed by the manufacturer else N/A | A description of the marketing and pricing plans used in the launch of the new drug  |
|                       |                  |                                                     | This drug is a generic drug and marketed in traditional generic ways through typical |
| N                     | N                | N/A                                                 | wholesale and chargeback channels.                                                   |